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ABSTRACT
Paclitaxel is a microtubule-targeting agent widely used
for the treatment of many solid tumors. However,
patients show variable sensitivity to this drug, and
effective diagnostic tests predicting drug sensitivity
remain to be investigated. Herein, we show that the
expression of end-binding protein 1 (EB1), a regulator of
microtubule dynamics involved in multiple cellular
activities, in breast tumor tissues correlates with the
pathological response of tumors to paclitaxel-based
chemotherapy. In vitro cell proliferation assays reveal
that EB1 stimulates paclitaxel sensitivity in breast can-
cer cell lines. Our data further demonstrate that EB1
increases the activity of paclitaxel to cause mitotic
arrest and apoptosis in cancer cells. In addition, micro-
tubule binding afﬁnity analysis and polymerization/
depolymerization assays show that EB1 enhances pac-
litaxel binding to microtubules and stimulates the ability
of paclitaxel to promote microtubule assembly and sta-
bilization. These ﬁndings thus reveal EB1 as a critical
regulator of paclitaxel sensitivity and have important
implications in breast cancer chemotherapy.
KEYWORDS breast cancer, paclitaxel, microtubule, cell
proliferation, apoptosis, end-binding protein 1,
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INTRODUCTION
Microtubules are a component of the cytoskeleton and play a
crucial role in diverse cellular activities. Microtubules are
highly dynamic, and the dynamic properties are spatiotem-
porally regulated by microtubule-interacting proteins (Amos
and Schlieper, 2005). End-binding protein 1 (EB1) is a key
member of microtubule plus-end tracking proteins and is
regarded as the master regulator at microtubule plus ends.
EB1 tracks the plus ends of growing microtubules and
thereby regulates microtubule dynamic instability (Akhma-
nova and Steinmetz, 2008; Schuyler and Pellman, 2001).
EB1 promotes cell migration by stabilizing microtubules at
the cell cortex and is also involved in mitotic progression
(Asakawa and Toda, 2006; Li et al., 2011; Strickland et al.,
2005; Wen et al., 2004). Recent studies point out that EB1
regulates microtubule dynamics through promoting persis-
tent microtubule growth (Bieling et al., 2007; Li et al., 2011;
Strickland et al., 2005; Wen et al., 2004; Zovko et al., 2008).
EB1 is also a cofactor for many other microtubule-interacting
proteins, which interact with EB1 directly or require EB1 for
their efﬁcient plus-end accumulation (Akhmanova and
Steinmetz, 2008; Bieling et al., 2007; Dragestein et al., 2008;
Galjart, 2010; Honnappa et al., 2009; Jiang and Akhmanova,
2011; Kronja et al., 2009).
Paclitaxel is a microtubule-targeting agent widely utilized
in the clinic for the treatment of patients with breast cancer
and several other solid tumors. Paclitaxel stabilizes micro-
tubules and inhibits them from disassembly. As a result,
chromosomes fail to achieve the metaphase spindle
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conﬁguration, which further interferes with chromosome
separation and leads to apoptosis (Blagosklonny et al.,
2006; Dumontet and Jordan, 2010; Ikui et al., 2005). Pac-
litaxel has offered substantial improvement in patient sur-
vival, but the drug is not effective to all clinical cases. No
useful predictive marker exists because of the limited
understanding of the mechanisms regulating paclitaxel
sensitivity (Dumontet and Jordan, 2010). Recent studies
suggest a function of microtubule-interacting proteins in
modulating cancer cell sensitivity to microtubule-targeting
drugs, although the precise molecular mechanisms remain
elusive (Mohan et al., 2013; Rouzier et al., 2005; Sun et al.,
2012; Veitia et al., 2000; Wagner et al., 2005; Wang et al.,
2009). Our previous study has demonstrated an oncogenic
function of EB1 in breast cancer and show that its expres-
sion varies in different cancer cell lines (Dong et al., 2010;
Sun et al., 2008). These ﬁndings prompt us to explore the
potential role of EB1 in regulating paclitaxel sensitivity in
breast cancer and the underlying molecular mechanisms.
RESULTS
EB1 expression in breast tumor tissues correlates with
tumor response to paclitaxel-containing chemotherapy
To study the relationship between EB1 and paclitaxel sen-
sitivity, we acquired tumor tissues from breast cancer
patients who received neoadjuvant chemotherapy and then
underwent surgical resection. Among these patients, 54
cases received paclitaxel-containing chemotherapy, and 45
cases received a control regimen without paclitaxel. We
examined EB1 expression in tumor tissues and tissues
adjacent to tumor by immunohistochemistry. The samples
were classiﬁed into four groups according to EB1 expres-
sion, including negative staining (−), low staining (+), med-
ium staining (++), and high staining (+++) (Fig. 1A and 1D).
We found that EB1 expression varied signiﬁcantly among
patients. Out of the total samples, 18 were EB1-negative
(10 received paclitaxel-containing chemotherapy and 8
received control treatment), 24 had low staining (12
received paclitaxel-containing chemotherapy and 12
received control treatment), 28 had medium staining (16
received paclitaxel-containing chemotherapy and 12
received control treatment), and 29 showed high staining
(16 received paclitaxel-containing chemotherapy and 13
received control treatment).
By analyzing the correlation of EB1 expression with the
pathological response of tumors to paclitaxel-containing
treatment, we found a signiﬁcant positive correlation
between them (r = 0.427, P = 0.007) (Fig. 1B). In contrast,
there was no obvious correlation between EB1 expression
and tumor response to control treatment (r = 0.091,
P = 0.086) (Fig. 1C). Furthermore, EB1 expression in tis-
sues adjacent to tumor did not correlate with tumor response
to paclitaxel-containing chemotherapy (r = 0.064, P = 0.067)
or to the control regimen (r = 0.033, P = 0.075) (Fig. 1E and
1F). These results suggest that EB1 expression in breast
tumor tissues might predict tumor sensitivity to paclitaxel-
based treatment.
EB1 enhances paclitaxel sensitivity in breast cancer
cells
We then checked whether EB1 expression associates with
paclitaxel sensitivity in breast cancer cell lines. We examined
EB1 expression in T47D, ZR-75-1, SW527, MDA-MB-231,
and MCF7 breast cancer cell lines by immunoblotting and
then analyzed the expression level. Consistent with previous
studies (Dong et al., 2010), EB1 expression levels varied
among different cell lines; ZR-75-1, MDA-MB-231, and
MCF7 cells displayed much higher EB1 levels than T47D
and SW527 cells (Fig. 2A and 2B). Next, we examined the
sensitivity of these cells to different drugs, including the
microtubule-targeting agents paclitaxel and vinblastine, and
a speciﬁc inhibitor of the microtubule-dependent mitotic
kinesin Eg5, dimethylenastron (Liu et al., 2008), which was
used as a non-microtubule-drug control. Cells were treated
with the drugs at a series of concentrations and stained with
sulforhodamine B, a dye that binds stoichiometrically to all
cellular protein components, as a measure of cell prolifera-
tion (Vichai and Kirtikara, 2006). The IC50 value of each
drug, which represents the drug concentration needed for
inhibition of cell proliferation by 50%, was then calculated.
T47D and SW527, which had low EB1 expression, showed
relatively high IC50 values of paclitaxel and vinblastine
(Fig. 2C). Intriguingly, MDA-MB-231 cells expressed abun-
dant EB1, yet they were rather resistant to paclitaxel
(Fig. 2AC). Nevertheless, we found a remarkable negative
correlation of EB1 expression with the IC50 values of pac-
litaxel (r = 0.546) and vinblastine (r = 0.512), but not with
dimethylenastron (r = 0.198) (Fig. 2D). These results sug-
gest that EB1 might increase the sensitivity of breast cancer
cell lines to paclitaxel and vinblastine.
To gain more insights into the role of EB1 in regulating
tumor cell sensitivity to microtubule-targeting drugs, we
altered EB1 expression in MCF7 cells and then studied
the change of drug sensitivity. MCF7 cells were chosen
primarily due to their expression of a good amount of EB1
and their frequent use in the study of the mechanisms of
action of microtubule-targeting agents. Cells were trans-
fected with EB1 speciﬁc small interfering RNAs (siRNAs),
which could knockdown EB1 expression efﬁciently
(Fig. 2E), and stained with sulforhodamine B to analyze
the IC50 values. EB1 siRNAs remarkably increased the
IC50 values of paclitaxel, but did not obviously affect the
IC50 values of vinblastine or dimethylenastron (Fig. 2F).
These data indicate a speciﬁc effect of EB1 on paclitaxel
sensitivity. We also transfected cells with different doses of
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GFP-EB1 or GFP and then analyzed the effect of EB1
overexpression on paclitaxel sensitivity. Overexpression of
GFP did not affect the IC50 value of paclitaxel (Fig. 2G
and 2H). In contrast, GFP-EB1 rendered cells more sen-
sitive to paclitaxel as shown by decreased IC50 values
(Fig. 2G and 2H).
We next investigated whether EB1 regulates paclitaxel
sensitivity in cell lines that represent different types of breast
cancer, including the estrogen receptor (ER)-positive cell line
MCF7, the human epidermal growth factor receptor 2
(HER2)-positive cell line SKBR3, and the triple-negative cell
line MDA-MB-231 (Neve et al., 2006). By MTT assays, we
found that EB1 siRNAs increased the IC50 values of paclit-
axel in all these cell lines (Fig. 2I). These data further dem-
onstrate that EB1 enhances paclitaxel sensitivity in breast
cancer cells.
EB1 promotes the activity of paclitaxel to induce mitotic
arrest and apoptosis
We then sought to investigate the molecular mechanism of
how EB1 regulates paclitaxel sensitivity. We analyzed mitotic
arrest and apoptosis, two key cellular events following pac-
litaxel treatment (Jordan and Wilson, 2004). MCF7 cells
transfected with control or EB1 siRNAs were treated with
paclitaxel for 24 h, and the morphology of cells was photo-
graphed. The percentage of round cells was dramatically
decreased by EB1 siRNAs as compared with control siRNA,
indicating that EB1 siRNAs compromised the ability of pac-
litaxel to induce mitotic arrest (Fig. 3A and 3B). The
decrease of paclitaxel-induced mitotic arrest by EB1 siRNAs
was conﬁrmed by the reduction of cells with 4N chromo-
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Figure 1. EB1 expression in breast tumor tissues correlates with tumor response to paclitaxel. (A) Immunohistochemical
analysis of EB1 expression in breast carcinoma tissues. (B) Correlation analysis of EB1 expression in tumor tissues with tumor
response to paclitaxel-containing chemotherapy. (C) Correlation analysis of EB1 expression in tumor tissues with tumor response to
control chemotherapy. (D) Immunohistochemical analysis of EB1 expression in tissues adjacent to tumor. (E) Correlation analysis of
EB1 expression in adjacent tissues with tumor response to paclitaxel-containing chemotherapy. (F) Correlation analysis of EB1
expression in adjacent tissues with tumor response to control chemotherapy. The percentage of response to the treatment was
quantiﬁed as the number of responders divided by the number of total patients. The correlation between EB1 expression and the
pathological response was examined by Wilcoxon rank sum test. r, correlation coefﬁcient; P, statistical signiﬁcance.
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By staining cells with the DNA dye propidium iodide, we
further found that EB1 siRNAs remarkably inhibited the
activity of paclitaxel to induce apoptosis (Fig. 3D and 3E).
The inhibitory effect of EB1 siRNAs on paclitaxel-induced
apoptosis was conﬁrmed by quantiﬁcation of the percentage
of annexin V-positive cells (Fig. 3F). To verify the above
effects of EB1, we analyzed the effect of EB1 overexpres-
sion on paclitaxel-induced apoptosis. Cells were transfected
with GFP-EB1 or GFP and then treated with paclitaxel for




































































































































































































































Figure 2. EB1 expression increases paclitaxel sensitivity in breast cancer cell lines. (A) Immunoblot analysis of EB1 and actin
expression in breast cancer cell lines. (B) Experiments were performed as in (A), and relative EB1 expression was shown as the ratio
of EB1 intensity to actin intensity quantiﬁed by densitometry. (C) Cancer cells were treated with paclitaxel (PTX), vinblastine (VBL), or
dimethylenastron (DIMEN), and the IC50 values of the drugs were determined by sulforhodamine B staining. (D) Correlation analysis
between EB1 expression in the cancer cell lines and the IC50 values of different drugs, examined by Spearman rank correlation test.
(E) Immunoblot analysis of EB1 and actin expression in MCF7 cells transfected with control or two different EB1 siRNAs. (F) Cells
transfected with different siRNAs were treated with paclitaxel (PTX), vinblastine (VBL), or dimethylenastron (DIMEN), and the IC50
values of the drugs were determined. (G) Immunoblot analysis of GFP, GFP-EB1, and actin expression in MCF7 cells transfected with
different doses of GFP or GFP-EB1. (H) Cells transfected with different doses of GFP or GFP-EB1 plasmids were treated with
paclitaxel, and the IC50 values of paclitaxel were then determined. (I) Cells transfected with control or EB1 siRNAs were treated with
paclitaxel, and the IC50 values were determined by the MTT assay. Data shown in the graphs are means from three independent
experiments.
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increased the ability of paclitaxel to induce the formation of
aberrant nuclei, which is a characteristic of apoptosis. The
enhancing effect of GFP-EB1 on paclitaxel-induced apop-
tosis was further conﬁrmed by annexin V staining assay
(Fig. 3I). Altogether, these results reveal that EB1 promotes
the activity of paclitaxel to induce mitotic arrest and
apoptosis.
EB1 enhances the activity of paclitaxel to stimulate
microtubule assembly and stabilization
The activity of paclitaxel to trigger mitotic arrest and apop-
tosis results primarily from its effect on microtubule assembly
and stabilization (Jordan and Wilson, 2004). To gain more
mechanistic insight into the action of EB1 in modulating
paclitaxel sensitivity, we transfected MCF7 cells with GFP or
GFP-EB1 and then treated cells with paclitaxel (2 nmol/L).
The percentage of cells with microtubule bundles was ana-
lyzed by immunoﬂuorescence. As shown in Fig. 4A and 4B,
GFP-EB1 signiﬁcantly increased the ability of paclitaxel to
induce microtubule bundles, as compared with GFP or the
mock control.
To investigate the effect of EB1 on paclitaxel-mediated
microtubule assembly in vitro, we puriﬁed GST and GST-
EB1 from E. coli (Fig. 4C), and then analyzed their effects
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Figure 3. EB1 promotes the activity of paclitaxel to induce mitotic arrest and apoptosis. (A) MCF7 cells transfected with control
or EB1 siRNAs were treated with 2 nmol/L paclitaxel for 24 h, and the images of cells were taken by phase contrast microscopy. (B)
Experiments were performed as in (A), and the percentage of round cells was quantiﬁed. (C) MCF7 cells transfected with control or
EB1 siRNAs were treated with 2 nmol/L paclitaxel for 24 h, and the percentage of cells having 4N chromosomes was quantiﬁed by
ﬂow cytometric analysis of DNA content. (D) MCF7 cells transfected with control or EB1 siRNAs were treated with 2 nmol/L paclitaxel
for 48 h and stained with the DNA dye propidium iodide, and the images of cellular nuclei were taken. (E) Experiments were
performed as in (D), and the percentage of apoptotic cells was quantiﬁed. (F) MCF7 cells transfected with control or EB1 siRNAs were
treated with 2 nmol/L paclitaxel for 48 h and stained with PE-conjugated annexin V, and the percentage of annexin V-positive cells
was quantiﬁed. (G) MCF7 cells transfected with GFP or GFP-EB1 were treated with 2 nmol/L paclitaxel for 48 h and stained with
propidium iodide, and the images of cells were taken. (H) Experiments were performed as in (G), and the percentage of cells with
aberrant nuclei was quantiﬁed. Aberrant nuclei refer to nuclei with abnormal morphology, such as fragmented nuclei or nuclei with
irregular shapes. (I) MCF7 cells transfected with GFP or GFP-EB1 were treated with 2 nmol/L paclitaxel for 48 h and stained with PE-
conjugated annexin V, and the percentage of annexin V-positive cells was quantiﬁed.
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Figure 4. EB1 enhances the activity of paclitaxel to stimulate microtubule assembly. (A) MCF7 cells were transfected with GFP
or GFP-EB1 and then treated with vehicle (DMSO) or paclitaxel (2 nmol/L) for 12 h. Cells were stained with anti-α-tubulin antibody
and the DNA dye DAPI. (B) Experiments were performed as in (A), and the percentage of cells with microtubule bundles was
quantiﬁed by counting 300 cells from 20 ﬁelds. (C) Coomassie blue staining of GST and GST-EB1 proteins puriﬁed from E. coli. (D)
The mixture of MAP-free tubulin and rhodamine-labeled tubulin (9:1) was incubated at 37°C with puriﬁed GST or GST-EB1 in the
absence or presence of paclitaxel. The morphology of polymerized microtubules was then analyzed under the ﬂuorescence
microscope. (E) Experiments were performed as (D), and the intensity of microtubules was measured and normalized to the control
group. (F) MAP-free tubulin was incubated with puriﬁed GST or GST-EB1 at 37°C in the absence or presence of paclitaxel. The
polymerization of tubulin into microtubules was examined by measuring the optical absorbance at 350 nm of wavelength.
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of tubulin and rhodamine-labeled tubulin was incubated
with puriﬁed GST or GST-EB1 in the presence or absence
of paclitaxel at 37°C and the polymerized microtubules
were analyzed under the ﬂuorescence microscope. Con-
sistent with previous studies (Bu and Su, 2001; Vitre et al.,
2008), EB1 alone could modestly promote microtubule
polymerization/bundling in vitro. Importantly, EB1 greatly
enhanced the ability of paclitaxel to stimulate microtubule
assembly/bundling (Fig. 4D and 4E). We also examined
microtubule assembly in vitro over time by measuring the
changes in optical absorbance at 350-nm wavelength. In
agreement with the above ﬁndings, EB1 increased the
ability of paclitaxel to induce microtubule assembly over
time (Fig. 4F).
Next, we sought to investigate the effect of EB1 on pac-
litaxel induced microtubule stabilization. MCF7 cells were
transfected with GFP-EB1 or GFP followed by treatment with
paclitaxel (2 nmol/L). Microtubules were then placed on ice
for 30 min to depolymerize microtubules, and the percentage
of cells containing microtubules was quantiﬁed to evaluate
microtubule stability. We found that GFP-EB1, but not GFP,
could greatly enhance the ability of paclitaxel to stabilize
microtubules (Fig. 5A and 5B).
EB1 promotes paclitaxel binding to microtubules
To understand the underlying mechanism of how EB1































































































Figure 5. EB1 increases the ability of paclitaxel to stabilize microtubules and stimulates paclitaxel binding to microtubules.
(A) MCF7 cells were transfected with GFP or GFP-EB1 and treated with vehicle (DMSO) or paclitaxel (2 nmol/L). Cells were then
placed on ice for 30 min to depolymerize microtubules and stained with anti-α-tubulin antibody. (B) Experiments were performed as in
(A), and the percentage of cells containing microtubules was quantiﬁed. (C) Puriﬁed GSTor GST-EB1 at the indicated concentrations
(mol/L) on the x-axis was incubated with tubulin for 30 min at 37°C, and 3H-paclitaxel was added and incubated for another 30 min.
Microtubules were pelleted by centrifugation and the radioactivity present in the pellet was measured. (D) Experiments were
performed as in (C), except that gradient concentrations of 3H-paclitaxel were added to calculate the association constant (Ka)
between paclitaxel and microtubules as a measure of their binding afﬁnity.
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stabilization, we investigated the inﬂuence of EB1 on the
paclitaxel-microtubule interaction. We found that GST-EB1
could enhance paclitaxel binding to microtubules in a dose-
dependent manner (Fig. 5C). To conﬁrm the increase of the
paclitaxel-microtubule association by EB1, we analyzed the
association constant (Ka) between paclitaxel and microtu-
bules, as a measure of their binding afﬁnity. As shown in
Fig. 5D, GST-EB1 could increase the paclitaxel-microtubule
association constant in a dose-dependent manner. These
data thus reveal that EB1 promotes paclitaxel binding to
microtubules.
DISCUSSION
Microtubule dynamics are critical for many cellular activities,
such as cell division, cell migration, and cell polarization. EB1
acts as a key microtubule plus-end tracking protein and regu-
lator of microtubule dynamics (Akhmanova and Steinmetz,
2008). Manymicrotubule-interacting proteins, such as proteins
with CAP-Gly domains or SxIP motifs, rely on EB1 directly or
indirectly for their efﬁcient localizationatmicrotubulesplusends
(Bieling et al., 2007; Dragestein et al., 2008; Honnappa et al.,
2009; Kronja et al., 2009). Our previous studies have shown
that EB1 plays an oncogenic role in the development of breast
cancer (Dong et al., 2010). In the present study, we provide
several lines of evidencedemonstrating a novel functionofEB1
in regulating cancer cell sensitivity to the microtubule-targeting
agent paclitaxel: a) EB1 expression in breast tumor tissues
correlateswith thepathological responseof tumors topaclitaxel
treatment; b) EB1 expression correlates with paclitaxel sensi-
tivity in breast cancer cell lines; and c) knockdown of EB1
expression decreases paclitaxel sensitivity in breast cancer
cells and overexpression of EB1 has the opposite effect. Our
ﬁndings suggest that the expression of EB1might be used as a
marker for the prediction of the pathological response to pac-
litaxel-based chemotherapy. In addition, our results suggest a
possibility of improving the pathological response to paclitaxel
through modulating EB1 expression.
We have also explored the potential mechanism of how
EB1 regulates paclitaxel sensitivity in breast cancer cells. By
alteration of EB1 expression, we ﬁnd that EB1 could increase
the activity of paclitaxel to induce mitotic arrest and apopto-
sis, two hallmark events in paclitaxel-treated cells. Although
the casual relationship between paclitaxel-induced mitotic
arrest and apoptosis remains controversial (Jordan and Wil-
son, 2004), our data suggest that EB1 increases the ability of
paclitaxel to arrest cells at mitosis, resulting in increased
formation of multinucleated cells and ultimately leading to
enhanced apoptosis. By measuring the paclitaxel-microtu-
bule association constant and performing microtubule-asso-
ciated experiments in cells and in vitro, we ﬁnd that EB1
increases the binding afﬁnity between paclitaxel and micro-
tubules and promotes paclitaxel-mediated tubulin polymeri-
zation and stabilization. Together, these ﬁndings indicate that
EB1 promotes paclitaxel sensitivity in breast cancer cells by
enhancing the ability of paclitaxel to stimulate microtubule
assembly and stabilization and then cause mitotic arrest and
apoptosis.
It is worthy of note that, besides EB1 expression, other
factors such as tubulin subtypes and BCRA1 expression
have also been implicated in paclitaxel sensitivity, with
mechanisms involving paclitaxel-induced microtubule sta-
bilization (Quinn et al., 2007; Tommasi et al., 2007). It is
unclear currently whether EB1 exerts its effect independently
or acts in concert with other factors in regulating paclitaxel
sensitivity. In addition to the widely accepted notion that
paclitaxel exerts its anti-tumor effect through promoting
mitotic arrest in cancer cells and therefore cell death, there is
also compelling evidence suggesting that another key
mechanism of action of paclitaxel is promoting the activation
of caspase signaling pathways, in which caspase 8 has been
implicated (Komlodi-Pasztor et al., 2011). Thus, it would not
be surprising if more mechanisms were discovered in the
future as to how EB1 exerts its effect on paclitaxel sensitivity.
At present, it remains elusive how EB1 promotes paclit-
axel binding to microtubules. It is possible that EB1 enhances
the paclitaxel-microtubule interaction through structural or
allosteric effects in a pattern similar to several other micro-
tubule-binding proteins, such as Tau and CLIP-170 (Rouzier
et al., 2005; Sun et al., 2012). In addition, the interaction
between EB1 and paclitaxel in microtubule assembly may
ensure microtubules in a proper structure, so more paclitaxel
can bind to microtubules. Although our data show that EB1
promotes paclitaxel binding to microtubules in vitro, it is also
possible that EB1 may increase the ability of paclitaxel to
stimulate microtubule assembly via other mechanisms. For
example, the stabilization of microtubule plus ends by EB1
may promote the action of paclitaxel toward tubulin poly-
merization into microtubules. Alternatively, given that EB1
acts as a loading factor for many other microtubule-interact-
ing proteins in addition to its role as a regulator of microtubule
dynamics (Akhmanova and Steinmetz, 2008; Honnappa
et al., 2009), it is possible that EB1 may promote paclitaxel
sensitivity in breast cancer cells through interaction with
CLIP-170 or other microtubule plus end-tracking proteins.
Considering the potential of EB1 as a marker to predict
paclitaxel sensitivity or as a target to increase paclitaxel
sensitivity, the molecular mechanism of how EB1 regulates
paclitaxel sensitivity merits further investigation.
MATERIALS AND METHODS
Chemicals and antibodies
Paclitaxel, vinblastine, 4,6-diamidino-2-phenylindole (DAPI), and
sulforhodamineBwere purchased fromSigma-Aldrich (St. Louis,MO,
USA), phycoerythrin (PE)-conjugated annexin V was from Abcam
(Cambridge, MA, USA), dimethylenastron was fromCalbiochem (San
Diego, CA, USA), and 3H-paclitaxel was from Moravek Biochemicals
(Brea, CA, USA). Propidium iodide was purchased from Invitrogen
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(Carlsbad, CA, USA). Antibodies against EB1 (BD Biosciences, San
Jose, CA, USA), β-actin and α-tubulin (Sigma-Aldrich), and GFP
(Roche, Indianapolis, IN, USA), and horseradish peroxidase-conju-
gated secondary antibodies (Amersham Biosciences, Chandler, AZ,
USA) were obtained from the indicated sources. Microtubule-associ-
ated protein (MAP)-free tubulin and rhodamine-labelled tubulin were
from Cytoskeleton (Denver, CO, USA).
Plasmids, proteins, and siRNAs
The mammalian expression plasmid for GFP-EB1 and the bacterial
expression plasmid for GST-EB1 were constructed by cloning EB1
cDNA into the pEGFPN1 and pGEX6P3 vectors, respectively. The
BL21 (DE3) strain of E. coli was used to express the proteins, and
protein puriﬁcation was carried out by using glutathione Sepharose
4B beads according to the manufacturers instructions (Promega,
Fitchburg, WI, USA). EB1 and control luciferase siRNAs were syn-
thesized by Ribobio (Guangzhou, China).
Cell culture and transfection
T47D, ZR-75-1, SW527, MDA-MB-231, MCF7, and SKBR3 human
breast cancer cell lines were cultured in RPMI 1640 medium sup-
plemented with 10% fetal bovine serum at 37°C in a humidiﬁed
atmosphere with 5% CO2. Plasmids were transfected into cells with
the E-trans D reagent (Engreen, Beijing, China), and siRNAs were
transfected with the Lipofectamine 2000 reagent (Invitrogen, Carls-
bad, CA, USA).
Tumor samples and pathological analysis
Breast carcinoma specimens were obtained from breast cancer
patients who received neoadjuvant chemotherapy and then under-
went surgical resection at Shanxian Dongda Hospital, Shandong,
China. Of these patients, 54 were treated with a paclitaxel-contain-
ing regimen, and 45 were treated with a regimen without paclitaxel.
Tumor tissues were obtained by surgical resection. To measure the
pathological response of tumors, tumor specimens were cut into
small pieces, ﬁxed in formaldehyde, and embedded in parafﬁn.
Sections were stained with haematoxylin and eosin and micro-
scopically analyzed by an experienced pathologist for signs of tumor
regression, mainly characterized by tumor necrosis, decreased
tumor architectural detail, and replacement of tumor by ﬁbrosis. The
pathological response was deﬁned by the proportion of histological
changes in surgical specimens; responders showed histological
changes in two-thirds or more of tumor tissues.
Immunohistochemistry
For immunohistochemical analysis of EB1 expression, tissue sec-
tions were incubated with EB1 antibody and then with biotinylated
secondary antibody and streptavidin-biotin-peroxidase. Diam-
inobenzidine was used as a chromogen substrate, and haematoxylin
was used for counterstaining as described previously (Sun et al.,
2013). EB1 expression level was graded based on the intensity of
staining (0 = negative; 1 = low; 2 = medium; 3 = high) and the
percentage of stained cells (0 = 0% stained; 1 = 1%–25% stained;
2 = 26%–50% stained; 3 = 51%–100% stained). A multiplied score
(intensity score × percentage score) <2 was considered as negative
staining (−), 2–3 as low staining (+), 4–6 as medium staining (++)
and >6 as high staining (+++).
Immunoblot analysis
Protein samples were separated by SDS-PAGE and transferred onto
polyvinylidene diﬂuoride membranes (Millipore, New Bedford, MA,
USA). Then the membranes were blocked in 5% fat-free milk, and
incubated sequentially with primary antibodies and horseradish
peroxidase-conjugated secondary antibodies. Target proteins were
visualized with enhanced chemiluminescence detection reagent
according to the manufacturers instructions (Pierce Biotechnology,
Rock-ford, IL, USA).
In vitro cell proliferation assays
Cells were cultured in 96-well plates and treated for 48 h with dif-
ferent drugs with gradient concentrations. For the sulforhodamine B
staining assay, cells were then ﬁxed with 50% trichloroacetic acid,
stained with 0.4% sulforhodamine B and washed with 1% acetic
acid. The protein-bound dye was extracted with 10 mmol/L Tris base
and the optical density at 490-nm wavelength was determined. MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assays
were performed by using the Vybrant MTT Cell Proliferation Assay
Kit (Thermo Fisher Scientiﬁc, Norcross, GA, USA) following the
manufacturers instructions. The percentage of cell survival as a
function of drug concentration was plotted to determine the drug
concentration needed to prevent cell proliferation by 50% (IC50).
Immunoﬂuorescence microscopy
Cells grown on coverslips were ﬁxed with 4% paraformaldehyde at
room temperature or with methanol at 20C, and washed with
phosphate-buffered saline (PBS). The samples were blocked by
incubation with 2% bovine serum albumin in phosphate-buffered
saline. Cells were then stained with the DNA dye DAPI or propidium
iodide or PE-conjugated annexin V. The coverslips were ﬁnally
mounted with 90% glycerol in phosphate-buffered saline and
examined with an Axio Observer A1 microscope.
Flow cyometry analysis
Cells (2 × 106) were centrifuged, washed twice with ice-cold PBS, and
ﬁxed in 70% ethanol. Cells were centrifuged at 1000 ×g for 10 min,
and the supernatant was discarded. The pellets were resuspended in
the phosphate/citrate buffer (0.2 mol/L Na2HPO4/0.1 mol/L citric acid,
pH 7.5) at room temperature for 30 min. Cells were then washed with
5 mL of PBS and incubated with propidium iodide (20 μg/mL)/RNase
A (20 μg/mL) in PBS for 30 min. Samples were analyzed on a Coulter
Elite ﬂow cytometer (Beckman Coulter, Inc., Fullerton, CA).
In vitro tubulin polymerization assay
Spectrophotometer cuvettes held a mixture solution consisting of
puriﬁed GST or GST-EB1 in the buffer containing 100 mmol/L
PIPES, 1 mmol/L EGTA, 1 mmol/L MgSO4, and 1 mmol/L GTP. After
the addition of MAP-free tubulin, the cuvettes were transferred to a
temperature-controlled spectrophotometer and kept at 37°C. Tubulin
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polymerization was monitored by measuring the changes in absor-
bance at 350-nm wavelength as described previously (Huo et al.,
2011; Sun et al., 2011). In another group of experiments, 10% rho-
damine-labelled tubulin was added, and the polymerized microtu-
bules were ﬁxed, mounted onto slides, and examined with the
ﬂuorescence microscope.
Microtubule sedimentation
Different doses of puriﬁedGSTorGST-EB1was incubatedwith 10mol/
L MAP-free tubulin for 30 min at 37°C to induce microtubule assembly.
3H-paclitaxelwas thenaddedand themixturewas incubated foranother
30 min. Microtubules were pelleted through a sucrose layer by centri-
fugation, and the radioactivity in the pellet wasmeasured to analyze the
interaction between paclitaxel and microtubules. To measure the
association constant (Ka) between paclitaxel and microtubules, the
above experiments were performedwith gradient concentrations of 3H-
paclitaxel. The Ka was then calculated by the following equation:
Ka = radioactivity in the microtubule pellet/(concentration of total
tubulin used radioactivity of total paclitaxel used).
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